Citations

Mayo Clinic

Clear

1932 citation(s) found for "Nuñez, Jessica".

Predictors of exercise capacity following septal myectomy in patients with hypertrophic cardiomyopathy
Smith, Joshua R. , Layrisse, Veronica, Medina‐Inojosa, José R. , Berg, Jessica, Ommen, Steve R. , Olson, Thomas P. , Berg, Jessica D, Smith, Joshua R , Medina-Inojosa, José R

European Journal of Preventive Cardiology | January 22, 2020 | Volume: 27 | Issue: 10 | Pages: 1066-1073

10.1177/2047487319898106 | PMID 31967491 Get It

Aims Patients with hypertrophic obstructive cardiomyopathy (HOCM) have impaired exercise capacity. The gold standard therapy for patients with HOCM is septal myectomy surgery; however, changes in maximum oxygen uptake (VO2peak) following myectomy are variable, with VO2peak decreasing in some patients. Therefore, we evaluated changes in VO2peak following surgical myectomy to determine clinical predictors of those exhibiting decreased VO2peak post-myectomy. Methods HOCM patients ( N = 295) who performed symptom limited cardiopulmonary exercise testing prior to and following surgical myectomy were included for analysis. The VO2peak non-responder group ( n = 128) was defined as <0% change in VO2peak from pre- to post-myectomy. Step-wise regression models using demographics, clinical, and physiologic characteristics were created to determine predictors of hypertrophic cardiomyopathy patients in the VO2peak non-responder group. Results Independent predictors of the VO2peak non-responder group included higher pre-myectomy VO2peak (% predicted), older age, women, history of dyslipidemia, lack of cardiac rehabilitation enrollment, and lower body mass index (all p < 0.03). Forty-three (14.6%) patients reached the primary end-point of all-cause mortality during a median follow up of 11.25 years (interquartile range 6.94 to 16.40). After adjustment for age, sex, beta-blocker use, coronary artery disease history, and body mass index, the VO2peak non-responder group had greater risk of death compared with the VO2peak responder group (adjusted hazard ratio: 1.77, 95% confidence interval: 1.06–3.34, p = 0.01). Conclusion This large hypertrophic cardiomyopathy cohort demonstrated that demographic (i.e. female sex), lack of cardiac rehabilitation enrollment, and cardiovascular risk factors (i.e. history of dyslipidemia) are predictive of those patients that did not exhibit increases in VO2peak following septal myectomy surgery.
Proton minibeams—a springboard for physics, biology and clinical creativity
Dilmanian, F. Avraham, Venkatesulu, Bhanu Prasad , Sahoo, Narayan , Wu, Xiaodong , Nassimi, Jessica R., Herchko, Steven, Lu, Jiade J. , Eley, John G. , Krishnan, Sunil , Krishnan, Sunil , Dwarakanath, Bilikere Srinivasa Rao

The British Journal of Radiology | January 16, 2020 | Volume: 93 | Issue: 1107 | Pages: No page available

10.1259/bjr.20190332 | PMID 31944824 Get It

Proton minibeam therapy (PMBT) is a form of spatially fractionated radiotherapy wherein broad beam radiation is replaced with segmented minibeams—either parallel, planar minibeam arrays generated by a multislit collimator or scanned pencil beams that converge laterally at depth to create a uniform dose layer at the tumor. By doing so, the spatial pattern of entrance dose is considerably modified while still maintaining tumor dose and efficacy. Recent studies using computational modeling, phantom experiments, in vitro and in vivo preclinical models, and early clinical feasibility assessments suggest that unique physical and biological attributes of PMBT can be exploited for future clinical benefit. We outline some of the guiding principle of PMBT in this concise overview of this emerging area of preclinical and clinical research inquiry.
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort
Heuer, Hilary W. , Wang, P., Rascovsky, Katya, Bove, Jessica, Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Caso, Christine, Coppola, Giovanni , Dickerson, Brad C., Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrall, Jessica, Fields, Julie A. , Fishman, Ann, Forsberg, Leah K. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff-Radford, N. R., Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kornak, John , Kramer, Joel H. , Kraft, Ruth, Kremers, Walter K. , Kukull, Walter A. , Ljubenkov, Peter A. , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Rosen, Howard J. , Boxer, Adam L. , consortia, on behalf of the ARTFL and LEFFTDS, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Wolf, A., Appleby, Brian S. , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Kerwin, Diana , Knopman, David S. , Litvan, Irene , Potter, M., Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , consortia, on behalf of the ARTFL and LEFFTDS

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 60-70

10.1002/alz.12046 | PMID 31914226 Get It

AbstractIntroductionBehavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments.MethodsA total of 135 sporadic (s‐bvFTD; mean age 63.3 years; 34% female) and 99 familial (f‐bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f‐bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule‐associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation.ResultsParticipants with f‐bvFTD were younger and had earlier age at onset. s‐bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI‐Q) scores due to more frequent endorsement of depression and irritability.Discussionf‐bvFTD and s‐bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
Miyagawa, Toji , Brushaber, Danielle , Syrjanen, Jeremy A. , Kremers, Walter K. , Fields, Julie A. , Forsberg, Leah K. , Heuer, Hilary W. , Kornak, John , Boxer, Adam L. , Rosen, Howard J. , Bordelon, Yvette , Bove, Jessica, Brannelly, Patrick , Caso, Christina, Coppola, Giovanni , Dever, Reilly, Dheel, Christina, Dickinson, Susan, Domínguez, S. Carbajal, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrell, Jessica, Fishman, Ann, Gavrilova, Ralitza H. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kraft, Ruth, Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Multani, Namita, Onyike, Chiadi U. , Padmanabhan, Jaya , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Kate, Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Toga, Arthur W. , Trojanowski, John Q. , Wang, Ping , Weıntraub, Sandra , Wong, Bonnie , Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Knopman, David S. , Boeve, Bradley F. , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Kerwin, Diana , Litvan, Irene , Wszołek, Zbigniew K.

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 106-117

10.1002/alz.12033 | PMID 31914218 Get It

AbstractIntroductionWe created global rating scoring rules for the CDR® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD.MethodsThe CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants.ResultsThe CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non‐fluent/agrammatic variant primary progressive aphasia participants.DiscussionThe global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.
Multivesicular body and exosome pathway responses to acute exercise
Garner, Ron T. , Solfest, Jessica S., Nie, Yaohui , Kuang, Shihuan , Stout, Julianne , Gavin, Timothy P.

Experimental Physiology | January 9, 2020 | Volume: 105 | Issue: 3 | Pages: 511-521

10.1113/ep088017 | PMID 31917487 Get It

New Findings What is the central question of this study? What is the impact of acute aerobic and aerobic + resistance (concurrent) exercise on the regulation of multivesicular body formation in human skeletal muscle? What is the main finding and its importance? Gene expression for proteins associated with multivesicular body biogenesis was increased in response to concurrent exercise, and gene expression of microRNA processing (genetic information) was increased in response to aerobic and concurrent exercise. A greater understanding of the processing of multivesicular bodies in response to acute exercise may lead to novel treatments focused on intercellular communication pathways. AbstractRegular aerobic exercise (AEx) and resistance exercise (REx) promote many beneficial adaptations. Skeletal muscle participates in intercellular communication in part through the release of myokines and extracellular vesicles including exosomes (EXOs), the latter containing mRNA, microRNA (miRNA), lipids and proteins. Exercise‐induced regulation of skeletal muscle multivesicular body (MVB) biogenesis leading to EXO formation and release is poorly understood. We hypothesized that acute exercise would increase skeletal muscle MVB biogenesis and EXO release pathways with a greater response to aerobic + resistance exercise (A+REx) than to AEx alone. Twelve sedentary, healthy male subjects exercised on a cycle ergometer for 45 min (AEx) followed by single leg, knee extensor, resistance exercise (A+REx). Vastus lateralis biopsies were obtained at rest and 1 h post‐exercise. Key components of the MVB biogenesis, EXO biogenesis and release, and miRNA processing pathways were analysed. Clathrin and Alix mRNA (MVB biogenesis) were increased by A+REx, while DICER and exportin mRNA (miRNA processing) were increased by AEx and A+REx. There were positive relationships between MVBs and miRNA processing genes following both AEx and A+REx consistent with coordinated regulation of these interrelated processes (Alix mRNA increased with Drosha, exportin and Dicer mRNA). Acute exercise increases the regulation of components of MVB and EXO pathways as well as miRNA processing components. A greater understanding of the production and packaging of skeletal muscle MVBs, EXOs and mature miRNA could lead to novel treatments focused on intercellular communication.
Improving Augmented Human Intelligence to Distinguish Burkitt Lymphoma From Diffuse Large B-Cell Lymphoma Cases
Mohlman, Jeffrey S., Leventhal, Samuel , Hansen, Taft, Kohan, Jessica, Pascucci, Valerio , Salama, Mohamed E.

American Journal of Clinical Pathology | January 8, 2020 | Volume: 153 | Issue: 6 | Pages: 743-759

10.1093/ajcp/aqaa001 | PMID 32067039 Get It

AbstractObjectivesTo assess and improve the assistive role of a deep, densely connected convolutional neural network (CNN) to hematopathologists in differentiating histologic images of Burkitt lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL).MethodsA total of 10,818 images from BL (n = 34) and DLBCL (n = 36) cases were used to either train or apply different CNNs. Networks differed by number of training images and pixels of images, absence of color, pixel and staining augmentation, and depth of the network, among other parameters.ResultsCases classified correctly were 17 of 18 (94%), nine with 100% of images correct by the best performing network showing a receiver operating characteristic curve analysis area under the curve 0.92 for both DLBCL and BL. The best performing CNN used all available training images, two random subcrops per image of 448 × 448 pixels, random H&E staining image augmentation, random horizontal flipping of images, random alteration of contrast, reduction on validation error plateau of 15 epochs, block size of six, batch size of 32, and depth of 22. Other networks and decreasing training images had poorer performance.ConclusionsCNNs are promising augmented human intelligence tools for differentiating a subset of BL and DLBCL cases.
Evidence Regarding Medication Overuse Headache in Children and Adolescents: Protocol for a Systematic Review
VanderPluym, Juliana H. , Gautreaux, Jessica , Burch, Rebecca , Whitaker, Evans , Roberts, Jason , Turner, Dana P. , Gelfand, Amy A. , Roberts, Jason , Gelfand, Amy A , VanderPluym, Juliana

Headache: The Journal of Head and Face Pain | January 8, 2020 | Volume: 60 | Issue: 1 | Pages: 171-177

10.1111/head.13726 | PMID 31913513 Get It

Objectives This proposed systematic review will identify the existing evidence on medication‐overuse headache in children and adolescents. Background A number of medications have been shown to be effective for acute treatment of migraine in children and adolescents. However, patients may find they need to use their acute medications more frequently when migraine frequency is high. This has led to concern about their potential to develop medication‐overuse headache. Methods We will search PubMed, Embase, Web of Science, PsycINFO, and Cochrane databases from their inception to present time. We will also search conference proceedings of the last 4 scientific meetings of relevant societies and scan the reference lists of studies identified through the search. Study designs will include case series, cross‐sectional, cohort, case‐control, and interventional studies. Participants will include children and adolescents under 18 years of age with primary headache disorders. We aim to determine whether frequency of acute medication use is associated with headache frequency in children and adolescents. Outcomes of interest include: (1) headache frequency; (2) change in headache frequency, with time and in relationship to use of acute medications; and (3) headache‐related disability. We will also review data addressing treatment/management of medication overuse or medication‐overuse headache in children and adolescents. Relevant comparators will be withdrawal vs reduction of acute medication, initiation of preventive therapy vs no initiation with or without withdrawal of acute medication, and initiation of preventive therapy early vs late. Outcomes of interest include (1) days of acute medication use; (2) headache frequency; (3) change in headache frequency; and (4) headache‐related disability. After screening for inclusion, 2 team members will independently review and extract relevant data, and any discrepancies will be resolved through discussion and arbitration. We will assess risk of bias using appropriate tools (Cochrane Risk of Bias for randomized controlled trials (RCT) and Newcastle‐Ottawa Score for observational studies). Data will be summarized descriptively in text and tables. Results This systematic review will provide an overview of the available evidence on medication‐overuse headache in children and adolescents. Conclusions Findings from this review will aid clinicians by clarifying for them the current state of the evidence base, and will inform design of future research on this topic.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Brown, Patrick A. , Inaba, Hiroto , Annesley, Colleen , Beck, Jill C., Colace, Susan I. , Dallas, Mari , Kelly, Kara M. , Larrier, Nicole, Mahadeo, Kris M. , Nanda, Ronica H. , Nardi, Valentina , Rodriguez, Vilmarie , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Sun, Weili, Teachey, David T. , Wong, Victor , Yanik, Gregory A. , Johnson-Chilla, Alyse, Ogba, Ndiya , Inaba, Hiroto , DeSantes, Kenneth B , Kitko, Carrie L. , Lacayo, Norman James , Maese, Luke Devon , Silverman, Lewis B.

Journal of the National Comprehensive Cancer Network | January 7, 2020 | Volume: 18 | Issue: 1 | Pages: 81-112

10.6004/jnccn.2020.0001 | PMID 31910389 Get It

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.